Eli Lilly and Company (NYSE:LLY) Shares Purchased by Insigneo Advisory Services LLC

Insigneo Advisory Services LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 14.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,273 shares of the company's stock after purchasing an additional 777 shares during the period. Eli Lilly and Company accounts for 0.5% of Insigneo Advisory Services LLC's portfolio, making the stock its 26th largest position. Insigneo Advisory Services LLC's holdings in Eli Lilly and Company were worth $5,181,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. FPC Investment Advisory Inc. increased its position in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after acquiring an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $48,000. Highline Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 53.3% during the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after buying an additional 24 shares during the period. Finally, Capital A Wealth Management LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $63,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock traded down $6.96 during midday trading on Wednesday, reaching $784.28. The company had a trading volume of 2,441,727 shares, compared to its average volume of 3,656,356. The firm has a market capitalization of $743.29 billion, a PE ratio of 63.81, a P/E/G ratio of 1.16 and a beta of 0.40. The stock has a 50 day moving average price of $777.90 and a 200 day moving average price of $801.70. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue was up 45.2% on a year-over-year basis. During the same period last year, the business earned $2.58 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.